A Study of Two Dosage Forms of LY2886721 in Healthy Participants
Condition: Healthy Volunteers
Intervention: LY2886721 in a Capsule; LY2886721 in an orally disintegrating tablet (ODT)
Intervention description: Administered orally.; Administered orally.
Phase: Phase 1
Study type: Interventional
Primary purpose: Basic Science
Allocation: Randomized
Intervention model: Crossover Assignment
Masking: None (Open Label)
Enrollment: 26.0
Sex: All
Minimum age: 18 Years
Healthy volunteers: Accepts Healthy Volunteers

Summary:

      The purpose of this study is to evaluate two different formulations of LY2886721. In
      addition, this study will determine how much of study drug (LY2886721) gets into the blood
      steam and how long the body takes to get rid of it after taking each formulation with or
      without a meal. Information about any side effects that may occur will also be collected.
      Each participant may be involved in the study for approximately 7 weeks.

      This study requires 4 periods. In each period, participants will receive LY2886721 as a
      tablet or capsule, with or without food and water. There is a 7 day washout between each
      period.
    

Eligibility criteria:

        Inclusion Criteria:

          -  Have a body mass index (BMI) of 18.5 to 32.0 kilograms per square meter (kg/m^2),
             inclusive, at screening

          -  At least 4 participants who are greater than 55 years of age

          -  Male participants: Agree to use a reliable method of birth control and not donate
             sperm during the study and for 3 months following the last dose of the investigational
             product

          -  Female participants: Women not of child-bearing potential due to surgical
             sterilization (at least 6 weeks after surgical bilateral oophorectomy, hysterectomy,
             or both) confirmed by medical history, or postmenopausal females, as determined by
             medical history and physical examination (spontaneous amenorrhea for 6 to 12 months
             and a follicle stimulating hormone [FSH] level greater than 40 milli-international
             units per milliliter [mIU/mL])

          -  Have venous access sufficient to allow for blood sampling as per the protocol

        Exclusion Criteria:

          -  Are currently enrolled in, have completed, or discontinued within the last 30 days
             from a clinical trial involving an investigational product; or are concurrently
             enrolled in any other type of medical research judged not to be scientifically or
             medically compatible with this study

          -  Have participated, within the last 30 days, in a clinical trial involving an
             investigational product

          -  Have known allergies to LY2886721, related compounds, or any components of the
             formulation

          -  Have an abnormality in the 12-lead electrocardiogram (ECG)

          -  Have a significantly abnormal blood pressure as determined by the investigator

          -  Have a history or current cardiovascular, respiratory, hepatic, renal,
             gastrointestinal, endocrine, hematological, or neurological disorders capable of
             significantly altering the absorption, metabolism, or elimination of drugs; of
             constituting a risk when taking the study medication; or of interfering with the
             interpretation of data

          -  Regularly use known drugs of abuse and/or show positive findings on urinary drug
             screening

          -  Show evidence of human immunodeficiency virus (HIV) infection and/or positive human
             HIV antibodies

          -  Show evidence of hepatitis B or C and/or positive hepatitis B or C antibody

          -  Have a history of, or current, significant ophthalmologic disease

          -  Show evidence of significant active neuropsychiatric disease or history of suicide
             attempt